Pretreatment with tumor necrosis factor-α attenuates arterial hypotension and mortality induced by endotoxin in pigs

Critical Care Medicine

Volumn 28, Issue 6, 2000, Pages 2015-2021

  Murphey, E D ^a,b   Traber, Daniel L ^a  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Animal model; Anti inflammatory; Cytokine; Endotoxin; Hypotension; Interleukin 10; Shock; Swine; Systemic inflammatory response syndrome; Tumor necrosis factor

Indexed keywords

ENDOTOXIN; INTERLEUKIN 10; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; FEMALE; HYPOTENSION; MONONUCLEAR CELL; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SHOCK; SWINE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0033933163     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200006000-00056     Document Type: Article

References (70)

1. 1. Parker MM, Shelhamer JH, Natanson C, et al: Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: Heart rate as an early predictor of prognosis. Crit Care Med 1987; 15:923-929
2. 2. Suffredini AF, Fromm RE, Parker MM, et al: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321:280-287
3. 3. Murphey E, Lee S, Traber DL: Continuous, low-dose infusion of endotoxin results in chronic hyperdynamic shock in pigs. Abstr. FASEB J 1997; 11:A286
4. 4. Strieter RM, Kunkel SL, Bone RC: Role of tumor necrosis factor-α in disease states and inflammation. Crit Care Med 1993; 21: S447-S463
5. 5. Pinsky MR, Vincent JL, Deviere J, et al: Serum cytokine levels in human septic shock: Relation to multiple-system organ failure and mortality. Chest 1993; 103:565-575
6. 6. Lin RY, Astiz ME, Saxon JC, et al: Relationships between plasma cytokine concentrations and leukocyte functional antigen expression in patients with sepsis. Crit Care Med 1994; 22:1595-1602
7. 7. Martin C, Saux P, Mege JL, et al: Prognostic values of serum cytokines in septic shock. Intensive Care Med 1994; 20:272-277
8. 8. Sloane PJ, Elsasser TH, Spath JA, et al: Plasma tumor necrosis factor-α during long-term endotoxemia in awake sheep. J Appl Physiol 1992; 73:1831-1837
9. 9. Villa P, Sartor G, Angelini M, et al: Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin. Clin Diagn Lab Immunol 1995; 2:549-553
10. 10. Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-474
11. 11. Natanson C, Eichenholz PW, Danner RL, et al: Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 1989; 169:823-832
12. 12. Eichacker PQ, Hoffman WD, Farese A, et al: TNF but not IL-1 in dogs causes lethal lung injury and multiple organ dysfunction similar to human sepsis. J Appl Physiol 1991; 71:1979-1989
13. 13. Johnson J, Meyrick B, Jesmok G, et al: Human recombinant tumor necrosis factor α infusion mimics endotoxemia in awake sheep. J Appl Physiol 1989; 66:1448-1454
14. 14. Abraham E, Glauser MP, Butler T, et al: p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. JAMA 1997; 277: 1531-1538
15. 15. Fisher CJ Jr, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996; 334:1697-1702
16. 16. Cohen J, Carlet J: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 1996; 24:1431-1440
17. 17. Fisher CJ Jr, Opal SM, Dhainaut JF, et al: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21:318-327
18. 18. Echtenacher B, Falk W, Mannel DN, et al: Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145: 3762-3766
19. 19. Nakane A, Minagawa T, Kato K: Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988; 56: 2563-2569
20. 20. Pfeffer K, Matsuyama T, Kundig TM, et al: Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993; 73:457-467
21. 21. Livingston DH, Malangoni MA, Sonnenfeld G: Immune enhancement by tumor necrosis factor-α improves antibiotic efficacy after hemorrhagic shock. J Trauma 1989;29: 967-970
22. 22. Cross AS, Sadoff JC, Kelly N, et al: Pretreatment with recombinant murine tumor necrosis factor α/cachectin and murine interleukin-1 alpha protects mice from lethal bacterial infection. J Exp Med 1989; 169: 2021-2027
23. 23. Alexander HR, Doherty GM, Block MI, et al: Single-dose tumor necrosis factor protection against endotoxin-induced shock and tissue injury in rats. Infect Immun 1991; 59: 3889-3894
24. 24. Sheppard BC, Fraker DL, Norton JA: Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor. Surgery 1989;106:156-161
25. 25. Alexander HR, Sheppard BC, Jensen JC, et al: Treatment with recombinant human tumor necrosis factor-α protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. J Clin Invest 1991; 88: 34-39
26. 26. Dubois EF: The estimation of the surface area of the body. In: Basal Metabolism in Health and Disease. DuBois EF (Ed). Third Edition. Philadelphia, Lea & Febiger, 1936, pp 125-144
27. 27. Spriggs DR, Sherman ML, Michie H, et al: Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion: A phase I and pharmacologic study. J Natl Cancer Inst 1988; 80:1039-1044
28. 28. Creaven PJ, Plager JE, Dupere S, et al: Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1987; 20:137-144
29. 29. Blick M, Sherwin SA, Rosenblum M, et al: Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987; 47:2986-2989
30. 30. Feinberg B, Kurzrock R, Talpaz M, et al: A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988; 6:1328-1334
31. 31. Beutler BA, Milsark IW, Cerami A: Cachectin/ tumor necrosis factor: Production, distribution, and metabolic fate in vivo. J Immunol 1985; 135:3972-3977
32. 32. de Waal Malefyt R, Abrams J, Bennett B, et al: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-1220
33. 33. Wanidworanun C, Strober W: Predominant role of tumor necrosis factor-α in human monocyte interleukin-10 synthesis. J Immunol 1993; 151:6853-6861
34. 34. van der Poll T, Jansen J, Levi M, et al: Regulation of interleukin-10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med 1994; 180:1985-1988
35. 35. Kambayashi T, Jacob CO, Strassmann G: IL-4 and IL-13 modulate IL-10 release in endotoxin-stimulated murine peritoneal mononuclear phagocytes. Cell Immunol 1996; 171: 153-158
36. 36. Wang P, Wu P, Siegel MI, et al: IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J Immunol 1994; 153:811-816
37. 37. Fiorentino DF, Zlotnik A, Mosmann TR, et al: IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147: 3815-3822
38. 38. Barsig J, Kusters S, Vogt K, et al: Lipopolysaccharide-induced interleukin-10 in mice: Role of endogenous tumor necrosis factor-α. Eur J Immunol 1995; 25:2888-2893
39. 39. Sagawa K, Mochizuki M, Sugita S, et al: Suppression by IL-10 and IL-4 of cytokine production induced by two-way autologous mixed lymphocyte reaction. Cytokine 1996; 8:501-506
40. 40. Jenkins JK, Malyak M, Arend WP: The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 β production in human monocytes and neutrophils. Lymphokine Cytokine Res 1994; 13:47-54
41. 41. Cassatella MA, Meda L, Gasperini S, et al: Interleukin 10 (IL-10) up-regulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorpho-nuclear leukocytes by delaying mRNA degradation. J Exp Med 1994; 179:1695-1699
42. 42. Joyce DA, Gibbons DP, Green P, et al: Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol 1994; 24: 2699-2705
43. 43. Dickensheets HL, Freeman SL, Smith JM, et al: Interleukin-10 up-regulates tumor necrosis factor receptor type-II (p75) gene expression in endotoxin-stimulated human monocytes. Blood 1997; 90:4162-4171
44. 44. Howard M, Muchamuel T, Andrade S, et a;: Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993; 177:1205-1208
45. 45. Rongione AJ, Kusske AM, Ashley SW, et al: Interleukin-10 prevents early cytokine release in severe intraabdominal infection and sepsis. J Surg Res 1997; 70:107-112
46. 46. van der Poll T, Jansen PM, Montefut WJ: Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. J Immunol 1997; 158:1971-1975
47. 47. Sawa T, Corry DB, Gropper MA, et al: IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia. J Immunol 1997; 159:2858-2866
48. 48. Marchant A, Deviere J, Byl B, et al: Interleukin-10 production during septicemia. Lancet 1994; 343:707-708
49. 49. Parsons PE, Moss M, Vannice JL, et al: Circulating IL-1ra and IL-10 levels are increased but do not predict the development of acute respiratory distress syndrome in at-risk patients. Am J Respir Crit Care Med 1997; 155: 1469-1473
50. 50. Lyons A, Kelly JL, Rodrick ML, et al: Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection. Ann Surg 1997; 226:450-460
51. 51. Klava A, Windsor AC, Farmery SM: Interleukin-10: A role in the development of postoperative immunosuppression. Arch Surg 1997; 132:425-429
52. 52. Chernoff AE, Granowitz EV, Shapiro SM: A randomized, controlled trial of IL-10 in humans. J Immunol 1995; 154:5492-5499
53. 53. Ogle CK, Guo X, Chance WT, et al: Induction of endotoxin tolerance in rat bone marrow cells by in vivo infusion of tumor necrosis factor. Crit Care Med 1997; 25:827-833
54. 54. Goldbach JM, Roth J, Storr B, et al: Repeated infusions of TNF-α cause attenuation of the thermal response and influence LPS fever in guinea pigs. Am J Physiol 1996; 270: R749-R754
55. 55. Windsor AC, Mullen PG, Walsh CJ, et al: Delayed tumor necrosis factor α blockade attenuates pulmonary dysfunction and metabolic acidosis associated with experimental gram-negative sepsis. Arch Surg 1994; 129: 80-89
56. 56. Errol A, Fantuzzi G, Mengozzi M, et al: Differential refugulation of cytokine production in lipopolysaccharide tolerance in mice. Infect Immun 1993; 61:4356-4359
57. 57. Ziegler-Heitbrock HWL: Molecular mechanism in tolerance to lipopolysaccharide. J Inflamm 1995; 45:13-26
58. 58. Brown JM, Anderson BO, Repine JE, et al: Neutrophils contribute to TNF induced myocardial tolerance to ischemia. J Mol Cell Cardiol 1992; 24:485-495
59. 59. Keel M, Schregenberger N, Steckholzer U, et al: Endotoxin tolerance after severe injury and its regulatory mechanisms. J Trauma 1996; 41:430-438
60. 60. Schroder J, Stuber F, Gallati H, et al: Pattern of soluble TNF receptors I and II in sepsis. Infection 1995; 23:143-148
61. 61. Froon AH, Bemelmans MH, Greve JW, et al: Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: Correlation with plasma creatinine values. Crit Care Med 1994; 22:803-809
62. 62. van der Poll T, Jansen J, van Leenen D, et al: Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 1993; 168:955-960
63. 63. Mohler KM, Torrance DS, Smith CA, et al: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151:1548-1561
64. 64. Meng X, Brown JM, Ao L, et al: Endotoxin induces cardiac heat shock protein 70 and resistance to endotoxemic myocardial dysfunction. Am J Physiol 1996; 271: C1316-C1324
65. 65. Beutler B, Krochnin N, Milsark IW, et al: Control of cachectin (tumor necrosis factor) synthesis: Mechanisms for endotoxin resistance. Science 1986; 2332:977-980
66. 66. Lam C, Schutze E, Quakyi E, et al: SDZ MRL953, a novel synthetic lipid A analogue, induces tolerance to the lethal effects of endotoxin and enhances nonspecific immunity. Can J Infect Dis 1992; 3:94-100
67. 67. Ruggiero G, Andreana A, Utili R, et al: Enhanced phagocytosis and bacterial activity of hepatic reticuloendothelial system during endotoxin tolerance. Infect Immun 1980; 27: 798-803
68. 68. Izbicki JR, Raedler C, Anke A, et al: Beneficial effect of liposome-encapsulated muramyl tripeptide in experimental septicemia in a porcine model. Infect Immun 1991; 59: 126-130
69. 69. Ertel W, Kremer JP, Kenney J, et al: Down-regulation of proinflammatory cytokine release in whole blood from septic patients. Blood 1995; 85:1341-1347
70. 70. Munoz C, Carlet J, Fitting C, et al: Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991; 88:1747-1754